Page last updated: 2024-09-05

sk&f 107260 and lotrafiban

sk&f 107260 has been researched along with lotrafiban in 2 studies

Compound Research Comparison

Studies
(sk&f 107260)
Trials
(sk&f 107260)
Recent Studies (post-2010)
(sk&f 107260)
Studies
(lotrafiban)
Trials
(lotrafiban)
Recent Studies (post-2010) (lotrafiban)
11002648

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ali, FE; Barton, LS; Bondinell, WE; Burgess, JL; Callahan, JF; Calvo, RR; Chen, L; Chen, W; Erhard, K; Feuerstein, G; Heys, R; Huffman, WF; Hwang, SM; Jakas, DR; Keenan, RM; Ku, TW; Kwon, C; Lee, CP; Miller, WH; Newlander, KA; Nichols, A; Parker, M; Peishoff, CE; Rhodes, G; Ross, S; Samanen, JM; Shu, A; Simpson, R; Takata, D; Uzsinskas, I; Venslavsky, JW; Yellin, TO; Yuan, CK1
Gretler, DD; Scarborough, RM1

Reviews

1 review(s) available for sk&f 107260 and lotrafiban

ArticleYear
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.
    Journal of medicinal chemistry, 2000, Sep-21, Volume: 43, Issue:19

    Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Drug Design; Fibrinolytic Agents; Humans; Injections; Integrins; Molecular Mimicry; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Snake Venoms

2000

Other Studies

1 other study(ies) available for sk&f 107260 and lotrafiban

ArticleYear
Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists.
    Journal of medicinal chemistry, 1996, Dec-06, Volume: 39, Issue:25

    Topics: Administration, Oral; Benzodiazepinones; Humans; Platelet Glycoprotein GPIIb-IIIa Complex

1996